Ziopharm Oncology Inc. (ZIOP) Submits IND to FDA for Melanoma Therapeutic Candidate
Ziopharm Oncology Inc., a biopharmaceutical company focused on the development and commercialization of cancer therapeutics, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to commence a clinical study of the company’s therapeutic candidate for patients with melanoma. Ad-RTS-IL-12 (INXN 2001/1001) is a novel DNA-based therapeutic candidate. If the IND is approved, the phase I clinical study will be conducted to evaluate the safety of, and the immunological and biological effects of, the drug. Ad-RTS-IL12 is the second clinical oncology product candidate from the Ziopharm/Intrexon Corp. exclusive, synthetic biology channel partnership. "Cancer is…